Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Helius Medical Technologies (TSX:HSM) has authorised the company’s eighth PoNS Treatment centre, in Nanaimo, British Columbia. 
  • The Cline Medical Centre will make PoNS Treatment far more accessible to people all over Canada.
  • PoNS, or Portable Neuromodulation Stimulator, is a medical device that provides short-term treatment for balance disorders caused by brain injuries.
  • Helius is continuing to look for more potential clinics to offer PoNS Treatment.
  • Helius’s share price is up 0.71 per cent, with shares trading at $1.41 apiece.

Neurotech company Helius Medical Technologies (HSM) has authorised their eighth PoNS Treatment centre, this time in Nanaimo, British Columbia.

The PoNS, or Portable Neuromodulation Stimulator, is a non-implantable medical device that provides short-term treatment for chronic balance deficit. Chronic balance deficit is a balance disorder caused by mild-to-moderate traumatic brain injury.

The latest authorised clinic, the Cline Medical Centre, will make PoNS Treatment far more accessible to people suffering from such injuries.

Medical Director of Cline Medical Centre, Dr John Cline, MD, spoke positively about the ability to administer PoNS Treatment at his clinic.

“This will be the most important thing I do in my career. Cline Medical Centre is excited to announce the introduction of PoNS Treatment to our community.”

According to Dr Cline, “CMC will be the second clinic in BC to make this available to those patients suffering from mild-to-moderate traumatic brain injury.”

In addition to the Cline Medical Centre, PoNS Treatment is also currently available at 7 other authorised locations in Canada.

They are Neurotherapy Montreal in Montreal, Surrey Neuroplastic Clinic in Surrey, Advantage 4 Athletes Training Centre and Therapy Clinic in Markham, Synaptic Spinal Cord Injury and Neuro Rehabilitation Centre in Calgary, Apollo South Physical Therapy Centre in Ottawa, P3 Health Clinic in Toronto, and Clinique Cortex in Quebec City. 

Helius CEO, Phillipe Deschamps, described the company’s plan to authorise more clinics for PoNS Treatment in the future.

“Mild-to-moderate traumatic injuries impact the lives of millions of Canadians on a daily basis. We are continuing our search to identify and recruit accomplished clinics to deploy our PoNS technology. We look forward to expanding our clinic authorisations to serve more and more Canadians in the near future.”

Helius’s share price is up 0.71 per cent, with shares trading at $1.41 apiece.

More From The Market Herald
Featured Video Play Icon

" Sixth Wave (CSE:SIXW) announces rapid detection of E. Coli

Sixth Wave’s (SIXW) AMIPs prototype has detected E. Coli in as little as five minutes.

" Neovasc (TSX:NVCN) announces direct sales operations in the U.K.

Neovasc (NVCN) has expanded its direct sales operations in Europe to include the United Kingdom, effective July 1, 2022.
Lexagene Holdings - CEO, Dr. Jack Regan.

" LexaGene (TSXV:LXG) to host a webinar on the use of the MiQLab system to diagnose urinary tract infections

 LexaGene Holdings (LXG) and Dr. Jane Sykes will present a webinar entitled, “The Wave of the Future: In-Clinic PCR Diagnosis.”
BriaCell Therapeutics Corp

" BriaCell (TSX:BCT) partners with Waisman Biomanufacturing

BriaCell (BCT) has signed an agreement with Waisman Biomanufacturing to manufacture Bria-Pros for BriaCell’s anticipated clinical trial in advanced prostate cancer.